Research programme: anticancer immunotoxins - Chugai/Forerunner Pharma Research
Alternative Names: GD17-PE40Latest Information Update: 16 Jul 2016
At a glance
- Originator Chugai Pharmaceutical; Forerunner Pharma Research
- Class Immunotoxins
- Mechanism of Action Molecular chaperone GRP78 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 21 Apr 2009 Preclinical trials in Cancer in Japan (unspecified route)